Shionogi to buy IntraBio for $2B, adding the rare disease drug Aqneursa
- Shionogi will acquire Austin-based IntraBio for $2 billion in cash, making it a subsidiary of its US arm.
- The prize is Aqneursa, an oral therapy approved for Niemann-Pick disease type C and, since, for ataxia-telangiectasia.
- Closing is expected in November–December 2026.
💡 Points
Buying a commercial-stage asset outright is a shift for Shionogi, which has leaned on its anti-infective franchise and partnerships. A rare neurology product with two indications adds revenue with a modest sales force and a clear niche. The question is whether Aqneursa can grow past NPC and A-T.
Shionogi to pay $2B for IntraBio, a commercial rare disease biotech ↗